What Has Been The Historical And Current Growth Of The Recombinant DNA Technology Market?
The recombinant dna technology market has seen considerable growth due to a variety of factors.
• The market size of recombinant DNA technology has seen robust growth in recent times. The market's value is set to increase from $858.94 billion in 2024 to $920.82 billion in 2025, experiencing a compound annual growth rate (CAGR) of 7.2%. Factors such as increased healthcare needs, expansion of the biopharmaceutical industry, escalating invest in research and development, and the dawn of personalized medicine have all contributed to the growth observed in the historical period.
What are the Market Size and Expected Growth Rates for the Recombinant DNA Technology Market By 2029?
The Recombinant DNA Technology market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for recombinant DNA technology is projected to witness robust expansion in the coming years. The market is speculated to rise to $1318.72 billion by 2029, with a compound annual growth rate (CAGR) of 9.4%.
The surge expected in the forecast period can be credited to factors such as an increase in chronic conditions, the emergence of biotech startups, escalated biotech funding, worldwide expansion of biotech markets, consumer receptivity and enlightenment. Key trends during the forecast period encompass scientific breakthroughs, advances in gene editing, cell and gene treatments, creation of RNA-based therapies, applications in treating rare disorders, and the assimilation of AI and data.
Which Key Drivers Are Propelling The Recombinant DNA Technology Market's Growth?
The rise in chronic illnesses is predicted to accelerate the expansion of the recombinant DNA technology market. These chronic diseases are long-term conditions that require sustained medical attention and may restrict regular activities. Recombinant DNA technology has revolutionized healthcare by producing biopharmaceutical proteins used in medicine and swapping unhealthy genes for healthy ones via gene therapy, with the intent of curing diseases. For example, the World Health Organization, based in Switzerland, reported in February 2024 that there will be over 35 million new cancer cases by 2050, a 77% rise compared to the projected 20 million cases in 2022. Consequently, the surge in chronic diseases is fueling the growth of the recombinant DNA technology market.
What Are The Key Segments Within The Global Recombinant DNA Technology Market?
The recombinant DNA technology market covered in this report is segmented –
1) By Product Type: Recombinant Protein Drugs, Vaccines, Genetically Modified Crops, Expression Systems, Cell And Gene Therapy, Gene Editing
2) By Component Type: Expression System, Cloning Vector
3) By Application Type: Food And Agriculture, Health And Disease, Environment, Other Application Types
4) By End-Use Type: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Other End-Use Types
Subsegments:
1) By Recombinant Protein Drugs: Hormones, Growth Factors
2) By Vaccines: Recombinant Viral Vaccines, Recombinant Bacterial Vaccines, Subunit Vaccines
3) By Genetically Modified Crops: Herbicide-Tolerant Crops, Insect-Resistant Crops, Nutritionally Enhanced Crop
4) By Expression Systems: Bacterial Expression Systems, Yeast Expression Systems, Mammalian Expression Systems
5) By Cell And Gene Therapy: Cell-Based Therapies, Gene Replacement Therapies, CAR T-Cell Therapies
6) By Gene Editing: CRISPR Or Cas9 Technologies, TALENs (Transcription Activator-Like Effector Nucleases), ZFNs (Zinc Finger Nucleases)
Pre-Book The Recombinant DNA Technology Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Recombinant DNA Technology Market?
The progress in technology is a significant trend in the recombinant DNA technology market. Leading companies active in this market are primarily focusing on cutting-edge technologies to maintain their market share. For instance, in August 2022, Bluebird bio, Inc., an American biotech firm, launched the U.S. Food and Drug Administration (FDA) approved product, ZYNTEGLO. This single dose gene therapy targets the genetic cause of beta-thalassemia, offering patients the opportunity to be free from continuous red blood cell transfusions. It uses an ex-vivo lentiviral vector to alter patient cells, making it the first FDA approved gene therapy for this disorder in the U.S, significantly reducing the lifelong management of beta-thalassemia.
Who Are the Key Players In The Recombinant DNA Technology Market?
Major companies operating in the recombinant DNA technology market include:
• Profacgen BioTech Corp.
• Amgen Inc.
• Novartis International AG
• GenScript Biotech Corporation
• Pfizer Inc.
• Novo Nordisk A/S
• Eli Lilly and Company
• Sanofi S.A.
• Merck & Co. Inc.
• Biogen Inc.
• GlaxoSmithKline PLC
• New England Biolabs Inc.
• Bayer CropScience
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd
• Regeneron Pharmaceuticals Inc.
• Gilead Sciences Inc.
• Moderna Inc.
• Vertex Pharmaceuticals Incorporated
• CRISPR Therapeutics AG
• Editas Medicine Inc.
• bluebird bio Inc.
• Illumina Inc.
• Qiagen N.V.
• Lonza Group AG
• Bio-Rad Laboratories Inc.
• Agilent Technologies Inc.
• Becton Dickinson and Company
• Sartorius AG
• Abcam PLC
• Horizon Discovery Group PLC
• Integrated DNA Technologies Inc.
• Twist Bioscience Corporation
• Synthego Corporation
• Codex DNA Inc.
• InvivoGen
• Eurofins Scientific SE
• Sarepta Therapeutics Inc.
• Sangamo Therapeutics Inc.
What Are The Regional Insights Into The Recombinant DNA Technology Market?
North America was the largest region in the recombinant DNA technology market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant DNA technology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
